Bringing evidence from press release to the clinic in the era of COVID-19.
Identifieur interne : 000654 ( Main/Corpus ); précédent : 000653; suivant : 000655Bringing evidence from press release to the clinic in the era of COVID-19.
Auteurs : James H. Mcmahon ; Michael J. Lydeamore ; Andrew J. StewardsonSource :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2021.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Dexamethasone, Hydroxychloroquine.
- drug therapy : COVID-19.
- epidemiology : COVID-19.
- methods : Clinical Trials as Topic.
- trends : Evidence-Based Medicine, Peer Review, Social Media.
- Humans.
Abstract
The urgent need to develop effective therapeutics and disseminate information from clinical studies has led to data from clinical trials being made available by alternate methods prior to peer-reviewed publication, including press releases, social media and pre-print papers. While this allows clinicians more open access to these data, a trust has to be placed with the investigators releasing these data without the availability of scientifically rigorous peer review. The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 have had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine. Clinicians and researchers must maintain a healthy scepticism when reviewing results prior to peer-reviewed publication, but also consider when these opportunities may allow for early implementation of potentially lifesaving interventions for people infected with COVID-19.
DOI: 10.1093/jac/dkaa506
PubMed: 33331867
PubMed Central: PMC7799029
Links to Exploration step
pubmed:33331867Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bringing evidence from press release to the clinic in the era of COVID-19.</title>
<author><name sortKey="Mcmahon, James H" sort="Mcmahon, James H" uniqKey="Mcmahon J" first="James H" last="Mcmahon">James H. Mcmahon</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lydeamore, Michael J" sort="Lydeamore, Michael J" uniqKey="Lydeamore M" first="Michael J" last="Lydeamore">Michael J. Lydeamore</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Victorian Department of Health and Human Services, Government of Victoria, Melbourne, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Stewardson, Andrew J" sort="Stewardson, Andrew J" uniqKey="Stewardson A" first="Andrew J" last="Stewardson">Andrew J. Stewardson</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33331867</idno>
<idno type="pmid">33331867</idno>
<idno type="doi">10.1093/jac/dkaa506</idno>
<idno type="pmc">PMC7799029</idno>
<idno type="wicri:Area/Main/Corpus">000654</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000654</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Bringing evidence from press release to the clinic in the era of COVID-19.</title>
<author><name sortKey="Mcmahon, James H" sort="Mcmahon, James H" uniqKey="Mcmahon J" first="James H" last="Mcmahon">James H. Mcmahon</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Lydeamore, Michael J" sort="Lydeamore, Michael J" uniqKey="Lydeamore M" first="Michael J" last="Lydeamore">Michael J. Lydeamore</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</nlm:affiliation>
</affiliation>
<affiliation><nlm:affiliation>Victorian Department of Health and Human Services, Government of Victoria, Melbourne, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Stewardson, Andrew J" sort="Stewardson, Andrew J" uniqKey="Stewardson A" first="Andrew J" last="Stewardson">Andrew J. Stewardson</name>
<affiliation><nlm:affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of antimicrobial chemotherapy</title>
<idno type="eISSN">1460-2091</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (drug therapy)</term>
<term>COVID-19 (epidemiology)</term>
<term>Clinical Trials as Topic (methods)</term>
<term>Dexamethasone (therapeutic use)</term>
<term>Evidence-Based Medicine (trends)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Peer Review (trends)</term>
<term>Social Media (trends)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dexamethasone</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Evidence-Based Medicine</term>
<term>Peer Review</term>
<term>Social Media</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The urgent need to develop effective therapeutics and disseminate information from clinical studies has led to data from clinical trials being made available by alternate methods prior to peer-reviewed publication, including press releases, social media and pre-print papers. While this allows clinicians more open access to these data, a trust has to be placed with the investigators releasing these data without the availability of scientifically rigorous peer review. The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 have had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine. Clinicians and researchers must maintain a healthy scepticism when reviewing results prior to peer-reviewed publication, but also consider when these opportunities may allow for early implementation of potentially lifesaving interventions for people infected with COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33331867</PMID>
<DateCompleted><Year>2021</Year>
<Month>02</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>02</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>76</Volume>
<Issue>3</Issue>
<PubDate><Year>2021</Year>
<Month>02</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of antimicrobial chemotherapy</Title>
<ISOAbbreviation>J Antimicrob Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>Bringing evidence from press release to the clinic in the era of COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>547-549</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/jac/dkaa506</ELocationID>
<Abstract><AbstractText>The urgent need to develop effective therapeutics and disseminate information from clinical studies has led to data from clinical trials being made available by alternate methods prior to peer-reviewed publication, including press releases, social media and pre-print papers. While this allows clinicians more open access to these data, a trust has to be placed with the investigators releasing these data without the availability of scientifically rigorous peer review. The examples of results from trials studying dexamethasone and hydroxychloroquine for treatment of COVID-19 have had contrasting outcomes, including the potential for significant numbers of lives saved with the early release of results from the RECOVERY trial studying dexamethasone contrasting with unsubstantiated data being presented from trials studying hydroxychloroquine. Clinicians and researchers must maintain a healthy scepticism when reviewing results prior to peer-reviewed publication, but also consider when these opportunities may allow for early implementation of potentially lifesaving interventions for people infected with COVID-19.</AbstractText>
<CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McMahon</LastName>
<ForeName>James H</ForeName>
<Initials>JH</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Monash Medical Centre, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lydeamore</LastName>
<ForeName>Michael J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Victorian Department of Health and Human Services, Government of Victoria, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stewardson</LastName>
<ForeName>Andrew J</ForeName>
<Initials>AJ</Initials>
<AffiliationInfo><Affiliation>Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Antimicrob Chemother</MedlineTA>
<NlmUniqueID>7513617</NlmUniqueID>
<ISSNLinking>0305-7453</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber>
<NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010380" MajorTopicYN="N">Peer Review</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061108" MajorTopicYN="N">Social Media</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>2</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>12</Month>
<Day>17</Day>
<Hour>12</Hour>
<Minute>7</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33331867</ArticleId>
<ArticleId IdType="pii">6040702</ArticleId>
<ArticleId IdType="doi">10.1093/jac/dkaa506</ArticleId>
<ArticleId IdType="pmc">PMC7799029</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000654 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000654 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:33331867 |texte= Bringing evidence from press release to the clinic in the era of COVID-19. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33331867" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |